Best GLP-1 Providers in New Hampshire (2026)

See by medication

Looking for a specific GLP-1? Browse New Hampshire providers by drug.

About GLP-1s in New Hampshire

New Hampshire permits telehealth GLP-1 prescribing. New Hampshire Medicaid offers limited GLP-1 coverage, primarily for diabetes patients.

• •New Hampshire's adult obesity rate is 30.2%
• •NH Medicaid offers limited GLP-1 coverage
• •Telehealth GLP-1 services are widely available statewide

Top Cities for GLP-1 Treatment in New Hampshire

Telehealth providers ship to all New Hampshire addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the New Hampshire GLP-1 clinic directory →

GLP-1 Care Access in New Hampshire: The Numbers

New Hampshire has 130 NPI-registered in-person weight-management clinics across 25 cities — 3 with an obesity-medicine taxonomy, 83 endocrinology, and 49 bariatric — alongside 97 telehealth programs that ship to New Hampshire addresses. The cheapest verified ongoing compounded semaglutide price available to New Hampshire residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in New Hampshire

In Q1 2026, New Hampshire Medicaid reimbursed approximately $3,857,848 across 3,913 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in New Hampshire cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $219/mo.

For the exact criteria, drug list, and appeal process, read our New Hampshire Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in New Hampshire

According to CDC data, 30.2% of New Hampshire adults have obesity (BMI of 30 or higher). This places New Hampshire at #34 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping New Hampshire residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions